Pediatric liver disease increases risk of developing type 2 diabetes
Nonalcoholic fatty liver disease (NAFLD) is the most common pediatric liver disease, affecting 5 to 8 million children in the United States. In NAFLD, the cells of the… read more.
Nonalcoholic fatty liver disease (NAFLD) is the most common pediatric liver disease, affecting 5 to 8 million children in the United States. In NAFLD, the cells of the… read more.
It is estimated that about one in four adults worldwide has a liver condition that is a risk factor for heart disease, according to a new American Heart… read more.
A clinical trial conducted by researchers from RCSI University of Medicine and Health Sciences and Beaumont Hospital Dublin has indicated an effective treatment for critically ill COVID-19 patients…. read more.
Women with long or irregular periods are known to have a higher risk of type 2 diabetes and heart disease, but researchers found these women may also be… read more.
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus… read more.
New instrument could aid diagnosis by helping surgeons pinpoint the best place for a biopsy. Researchers have developed an optical biopsy system that can distinguish between cancerous and… read more.
Albireo Pharma announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Bylvay (odevixibat) for the treatment of all types of progressive… read more.
Advanced liver cancer, or hepatocellular carcinoma (HCC), currently has limited treatment options and poor prognosis • A recent study introduces a new approach to treat advanced HCC by… read more.
First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from… read more.
High coffee consumption was associated with a lower risk for increased liver stiffness (a proxy for fibrosis) but not with steatosis, according to researchers at the University of… read more.
Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met… read more.
University of California – San Diego In mouse models of human disease, immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.